Brigitte Autran, Université de Pierre & Marie Curie, Paris, France - Biosketch |
Chair, Panel Discussion Session 3 : The role of new technologies in predicting efficacy and safety of new adjuvants and adjuvanted vaccines |
|
Max Bastian, Paul-Ehrlich-Institut, Langen, Germany - Biosketch |
Presentation Title: Bovine neonatal pancytopenia – Possible role of the adjuvant in a vaccine-induced fetal disease |
|
Steve Black, University of Cincinnati, Ohio, USA - Biosketch |
Chair, Session 1: What has been learned from recent experience |
|
Flora Castellino, Novartis, Sienna, Italy - Biosketch |
Presentation Title: Characterization of functional T-cells able to provide help for production of protective antibodies |
|
Bernard Charley, INRA, Jouy-en-Josas, France - Biosketch |
Presentation Title: Lessons from the veterinary field |
|
Behazine Combadière, Université Pierre & Marie Curie, Paris, France - Biosketch |
|
Giuseppe Del Giudice, Novartis, Sienna, Italy - Biosketch |
Chair, Session 3: The role of new technologies in predicting efficacy and safety of new adjuvants & adjuvanted vaccines |
|
Arnaud Didierlaurent, GlaxoSmithKline Biologicals, Rixensart, Belgium - Biosketch |
Presentation Title: Adjuvant studies in humans: Comparison of GSK adjuvant systems |
|
Wendy Fantl, Stanford University, Palo Alto, USA - Biosketch |
Presentation Title: Multidimensional Proteomic Single Cell Profiling by Mass Cytometry |
|
Marie-Joëlle Frachette, Sanofi Pasteur, Lyon, France - Biosketch |
Chair, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap? |
|
Joe Francica, VRC / NIH, Bethesda, Maryland, USA - Biosketch |
Presentation Title: Adjuvant studies in non-human primates (NHP) |
|
Martin Friede, WHO, Geneva, Switzerland - Biosketch |
Chair, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap? |
|
Bernard Fritzell, co-Chair, Human Vaccine Committee, IABS - Biosketch |
Introduction – Scope of meeting |
|
Nathalie Garçon, GlaxoSmithKline Biologicals, Rixensart, Belgium - Biosketch |
Chair, Session 1: What has been learned from recent experience |
|
Hana Golding, CBER / FDA, Bethesda, Maryland, USA - Biosketch |
Chair, Session IV: Regulatory challenges related to the licensure of adjuvanted vaccines |
|
Marion Gruber, FDA, USA - Biosketch |
Presentation Title: Current FDA policies related to adjuvanted vaccines |
|
Surender Khurana, CBER / FDA, Bethesda, Maryland, USA - Biosketch |
Presentation Title: Adjuvants, B cell epitope repertoire and antibody avidity |
|
David Lewis, University of Surrey, United Kingdom - Biosketch |
Chair, Panel Discussion, Session 2: What can be learned from animal models? What are their limitations? Can they be replaced by in vitro models? Can in vitro models fill the gap? |
|
Arnaud Marchant, Université Libre de Bruxelle, Belgium - Biosketch |
|
Gary Nabel, CVR / NIH, Bethesda, Maryland, USA - Biosketch |
Presentation Title: B cell repertoire and vaccination |
|
Helder Nayaka, Emory University, Atlanta, Georgia, USA - Biosketch |
Presentation Title: Systems biology to predict immunogenicity and safety of adjuvants |
|
Pieter Neels, EMA, United Kingdom - Biosketch |
Chair, Session IV: Regulatory challenges related to the licensure of adjuvanted vaccines |
|
Gerlinde Obermoser, Baylor Institute for Immunology Research, Dallas, Texas, USA - Biosketch |
Presentation Title: Systems biology to evaluate innate and acquired immunity after administration of vaccine / adjuvanted vaccine |
|
Marc Pallardy, Faculté de Pharmacie Paris-Sud, France - Biosketch |
Presentation Title: Current guidelines for pre-clinical evaluation, with focus on the gaps and difficulties in their application: a review |
|
John Petricciani, President, IABS - Biosketch |
Opening address |
|
Marina Zaitseva, CBER / FDA, Bethesda, Maryland, USA - Biosketch |
Presentation Title: In vitro assays and pre-clinical models to predict safety/reactogenicity in humans: the current state of the art |